NCT00549679 - Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

October 4, 2007

Primary Completion Date

December 15, 2008

Study Completion Date

December 15, 2008

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK256066

PDE4 inhibitor

DRUG

Placebo

Trial Locations (15)

10717

GSK Investigational Site, Berlin

13419

GSK Investigational Site, Tallinn

22291

GSK Investigational Site, Hamburg

33520

GSK Investigational Site, Tampere

82131

GSK Investigational Site, Gauting

150003

GSK Investigational Site, Yaroslavl

197022

GSK Investigational Site, Saint Petersburg

1624 NP

GSK Investigational Site, Hoorn

6085 NM

GSK Investigational Site, Horn

5504 DB

GSK Investigational Site, Veldhoven

656 045

GSK Investigational Site, Barnaul

105 077

GSK Investigational Site, Moscow

826 06

GSK Investigational Site, Bratislava

041 90

GSK Investigational Site, Košice

036 59

GSK Investigational Site, Martin